EP 1675599 A1 20060705 - PHARMACEUTICAL COMPOSITION COMPRISING OXOPLATIN, THE SALTS AND DERIVATIVES THEREOF
Title (en)
PHARMACEUTICAL COMPOSITION COMPRISING OXOPLATIN, THE SALTS AND DERIVATIVES THEREOF
Title (de)
PHARMAZEUTISCHE ZUSAMMENSETZUNG UMFASSEND OXOPLATIN, DESSEN SALZE UND DERIVATE
Title (fr)
COMPOSITION PHARMACEUTIQUE CONTENANT DE L'OXOPLATINE, SES SELS ET DERIVES
Publication
Application
Priority
- DE 2004002297 W 20041013
- EP 03090343 A 20031013
- US 51208303 P 20031020
- EP 04789999 A 20041013
Abstract (en)
[origin: EP1523984A1] Producing a pharmaceutical product containing cis-diammoniumdichlorotransdihydroxoplatinum(IV) (oxoplatin), where the composition is a tablet, capsule, coated tablet, suppository, ointment, cream, injection solution or infusion solution of defined composition, comprises preparing an oxoplatin-free base product and incorporating oxoplatin in the base product before pharmaceutical use. Producing a pharmaceutical product containing cis-diammoniumdichlorotransdihydroxoplatinum(IV) (oxoplatin), where the composition is a tablet, capsule, coated tablet, suppository, ointment, cream, injection solution or infusion solution as defined below, comprises preparing an oxoplatin-free base product and incorporating oxoplatin in the base product before pharmaceutical use: capsule comprising oxoplatin : silica : mannitol or magnesium stearate in a ratio of 0.1-10 : 0.1-10 : 0.1-10, tablet comprising cis-oxoplatin : lactose : corn starch : sodium carboxymethyl starch : calcium hydrogen phosphate dihydrate : cellulose powder : magnesium stearate in a ratio of 10-500 : 20-150 : 1-10 : 1-10 : 1-10 : 1-10 : 0.1-7, or cis-oxoplatin : silica : magnesium stearate in a ratio of 0.1-10 : 0.1-10 : 0.1-10, cream comprising cis-oxoplatin : benzyl alcohol : cetylstearyl alcohol : macrogol stearate 1000 : isopropyl palmitate : glycerol : sorbitol solution 70 % : water in a ratio of 0.2-8 : 0.1-7 : 1-10 : 0.1-7: 0.1-7 : 0.2-8 : 0.2-8 : 20-60, ointment comprising cis-oxoplatin : propylene glycol : macrogol stearate 1000 : cetylstearyl alcohol : petrolatum in a ratio of 2-20 : 5-40 : 0.1-7 : 1-10 : 25-400, gel comprising cis-oxoplatin : hydroxyethyl cellulose : chloroaerosol : sodium hydroxide : sodium hydrogen phosphate dihydrate : water in a ratio of 2-20 : 100-600 : 5-40 : 0.1-7 : 20-60 : 3000-50000, suppository comprising cis-oxoplatin : silica : hard fat in a ratio of 0.1-10 : 0.1-10 : 30-300, or cis-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silica : polysorbate 80 in a ratio of 10-100 : 700-4000 : 200-600 : 10-1000 : 10-1000 : 1-100 : 1-100 : 1-15 : 0.1-10, or cis-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silica : polysorbate 80 in a ratio of 10-100 : 1000-5000 : 300-1000 : 10-1000 : 10-1000 : 1-100 : 1-100 : 1-15 : 0.1-7, or cis-oxoplatin : lactose : corn starch : adipic acid : sodium hydrogen carbonate : stearic acid : magnesium stearate : silica : polysorbate 80 in a ratio of 10-1000 : 1500-5000 : 300-1000: 10-1000 : 10-1000: 1-100 : 1-100: 1-15 : 0.1-7, injection or infusion solution comprising cis-oxoplatin : benzyl alcohol : polysorbate 80 : sorbitol solution 70 % : water in a ratio of 0.2-8 : 1-10 : 0.1-7 : 100-800 : 100-400, or cis-oxoplatin : mannitol : water in a ratio of 0.1-7 : 5-40 : 1-10. An independent claim is also included for a pharmaceutical product as above. ACTIVITY : Cytostatic. cis-Oxoplatin had an IC50 of 3 mu g/ml against T47D breast cancer cells. MECHANISM OF ACTION : None given.
IPC 1-7
IPC 8 full level
A61K 9/00 (2006.01); A61K 9/02 (2006.01); A61K 9/20 (2006.01); A61K 9/48 (2006.01); A61K 33/24 (2019.01); A61K 33/243 (2019.01); A61K 47/06 (2006.01); A61K 47/10 (2006.01); A61K 47/14 (2006.01); A61K 47/26 (2006.01); A61K 47/38 (2006.01); A61P 35/00 (2006.01)
CPC (source: EP US)
A61K 9/0014 (2013.01 - EP US); A61K 9/0019 (2013.01 - EP US); A61K 9/0031 (2013.01 - EP US); A61K 9/0034 (2013.01 - EP US); A61K 9/02 (2013.01 - EP US); A61K 9/2009 (2013.01 - EP US); A61K 9/2018 (2013.01 - EP US); A61K 9/2054 (2013.01 - EP US); A61K 9/2059 (2013.01 - EP US); A61K 9/485 (2013.01 - EP US); A61K 9/4858 (2013.01 - EP US); A61K 31/282 (2013.01 - EP US); A61K 33/24 (2013.01 - EP US); A61K 33/243 (2018.12 - EP US); A61K 47/06 (2013.01 - EP US); A61K 47/10 (2013.01 - EP US); A61K 47/14 (2013.01 - EP US); A61K 47/26 (2013.01 - EP US); A61K 47/38 (2013.01 - EP US); A61P 35/00 (2017.12 - EP); A61P 35/02 (2017.12 - EP)
Citation (search report)
See references of WO 2005039605A1
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR
DOCDB simple family (publication)
EP 1523984 A1 20050420; EP 1523984 B1 20061206; AT E347367 T1 20061215; AU 2004283011 A1 20050506; AU 2004283011 B2 20091210; BR PI0415275 A 20070109; CA 2565097 A1 20050506; CA 2565097 C 20120821; CN 1867344 A 20061122; DE 50305909 D1 20070118; DK 1523984 T3 20070326; EP 1675599 A1 20060705; ES 2278115 T3 20070801; JP 2007508331 A 20070405; JP 4707668 B2 20110622; MX PA06003841 A 20070202; RU 2006116315 A 20071210; RU 2369396 C2 20091010; UA 88884 C2 20091210; US 2007048363 A1 20070301; US 7749534 B2 20100706; WO 2005039605 A1 20050506; ZA 200603019 B 20070725
DOCDB simple family (application)
EP 03090343 A 20031013; AT 03090343 T 20031013; AU 2004283011 A 20041013; BR PI0415275 A 20041013; CA 2565097 A 20041013; CN 200480029893 A 20041013; DE 2004002297 W 20041013; DE 50305909 T 20031013; DK 03090343 T 20031013; EP 04789999 A 20041013; ES 03090343 T 20031013; JP 2006534581 A 20041013; MX PA06003841 A 20041013; RU 2006116315 A 20041013; UA A200605217 A 20041013; US 59539904 A 20041013; ZA 200603019 A 20041013